Clinical Trial Update: Pediatric Hydroxyurea in Sickle Cell Anemia (PED HUG) [Phase 2]

View source ↗

Summary

The PED HUG Phase 2 trial evaluating hydroxyurea in pediatric sickle cell disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• HYDROXYUREA (Hydroxyurea)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Anemia, Sickle Cell, Hematologic Diseases | Phase 2 | Status: COMPLETED